title: [Effect of atorvastatin therapy on the level of secretory phospholipase A2 group IIA and on the modification of low density lipoproteins in patients with ischemic heart disease].
abstract: We studied effect of atorvastatin on secretory phospholipase A2 group IIA (sPLA2-IIA) in blood serum of patients with ischemic heart disease (IHD), lipid composition of low density lipoproteins (LDL) and process of modification of LDL induced by sPLA2-IIA in 20 patients taking 20 mg/day of atorvastatin for 3 months. In patients with initially high level of sPLA2-IIA ( > 8 mcg/l) its concentration significantly decreased. Amount of total cholesterol, triglyceride, lecithin, and lysolecithin remained unchanged, however in equimolar relations there occurred decrease of amount of total cholesterol and increase of cholesterol esters. At incubation of LDL, extracted from patient s plasma before initiation of the study, with human sPLA2-IIA from cardiac myxoma, 3.5 nmol of lysolecithin per 1 mg of LDL protein was formed while at incubation of LDL of same patients, extracted after 3 months of atorvastatin administration, amount of lysolecithin was 1.54 nmol/mg LDL protein. Thus atorvastatin therapy causes lowering of sPLA2-IIA in patients with initially high blood level of the enzyme and to a great extent precludes sPLA2-IIA induced LDL modification.
authors.forename: A A
authors.initials: AA
authors.lastname: Pirkova
authors.forename: E V
authors.initials: EV
authors.lastname: Samoĭlova
authors.forename: V A
authors.initials: VA
authors.lastname: Ameliushkina
authors.forename: A I
authors.initials: AI
authors.lastname: Kaminnyĭ
authors.forename: V N
authors.initials: VN
authors.lastname: Titov
authors.forename: N V
authors.initials: NV
authors.lastname: Prokazova
authors.forename: V G
authors.initials: VG
authors.lastname: Naumov
authors.forename: V V
authors.initials: VV
authors.lastname: Kucharchuk
authors.forename: A A
authors.initials: AA
authors.lastname: Korotaeva
mesh_terms: D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000069059:Atorvastatin; D002784:Cholesterol / Q000097:blood; D054501:Group II Phospholipases A2 / Q000097:blood* / Q000187:drug effects; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D054709:Lecithins / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood* / Q000187:drug effects; D008244:Lysophosphatidylcholines / Q000097:blood; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood* / Q000188:drug therapy*; D011758:Pyrroles / Q000627:therapeutic use*; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D054709:Lecithins; D008077:Lipoproteins, LDL; D008244:Lysophosphatidylcholines; D011758:Pyrroles; D014280:Triglycerides; D002784:Cholesterol; D000069059:Atorvastatin; D054501:Group II Phospholipases A2; C516287:PLA2G2A protein, human